HT-KIT Cancer Therapy Gains Momentum With Hoth Therapeutics And Aronnax Partnership

Hoth Therapeutics Inc., a biopharmaceutical company focused on patient care, has signed a Master Services Agreement with Aronnax, Inc. to advance its HT-KIT cancer treatment. HT-KIT, an antisense oligonucleotide targeting the proto-oncogene cKIT, is being developed for treating mast cell-related cancers and anaphylaxis. It has already received Orphan Drug Designation from the FDA. Research at NC State University has shown that HT-KIT effectively eliminates human mast cells dependent on KIT receptor signaling for survival.

A single dose provided effects lasting up to two weeks, with KIT expression significantly reduced for seven days. The results also revealed HT-KIT's capability to decrease KIT expression in GIST cells and induce cell death within 48 to 72 hours, while lowering KIT expression in AML cells over 72 hours. Aronnax will manage ITR Laboratories, the third-party provider conducting the intravenous injection study with varying doses. Each dose group will be spaced by forty-eight hours, and the study aims to provide Hoth with critical data on maximum dosage and range, aiding in the design of their upcoming clinical trial.

Robb Knie, CEO Of Hoth Therapeutics, “We continue to make quick progress in moving HT-KIT from the lab to patients. This further analysis will help us with that process, finalizing the protocols in our upcoming IND-enabling study. We are pleased to further engage Aronnax and ITR Laboratories on these key studies given their reputation for IND-enabling studies.”